Rebecca Hyde

I am excited to be partnered with the ADVI Health team! Together, I feel we are exceptionally positioned to enhance biopharma industry strategies, responding effectively to the rapidly evolving market dynamics of value-based care and healthcare quality. #biopharma #pharmaceuticalindustry #marketaccess #commercialstrategy #launchexcellence #healthequity #evidencegeneration #healthpolicy #valuebasedcare #qualitymeasurement #healthcarequality

90

24 Comments

❔ How do we position regional and community sites for success and mitigate risks for sponsors? ❔ In our new Oncology report, Parexel’s Karen McIntyre and Angela Hirst weigh in on why the traditional approach to site selection in oncology has created bottlenecks at major centers, potentially limiting patient access to life-changing therapies. 🚧 That’s why Parexel is bridging the gap by partnering with regional and community sites while still ensuring the high-quality standards of academic centers. Find out how: https://lnkd.in/etEhmCKC #ResearchSites #Oncology #NovelInsights

3

💥 Role of the MSL in Launch Preparedness 💥   Check out this weeks MSL Talk podcast with Matthew Goodwin, Vice President Medical Affairs at scPharmaceuticals who discusses the role of the MSL in preparation and strategy for launch preparedness of new products/indications   Learn more about….   👉 The importance of preparation and timeline for launch 👉 Training and resources for launch mode 👉 The role of field medical leadership 👉 Milestones and success factors to consider 👉 The stressors to be aware of and anticipate during a launch   The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers    

38

4 Comments

As I prepare to join you all tomorrow at the National Pharmaceutical Congress Institute webinar on Pharmacare featuring experts Mihai (Mike) Csaki, Zal Press, Pamela Fralick, and Eileen McMahon, I wanted to share my thoughts. I picked up 3 key pieces of information to put context, perspectives and opinions on this highly-debated reform. 1. Making contraception and diabetes medications free for Canadians The office of Prime Minister issued a communiqué on May 24. Extracts: ·      The medications many Canadians need are often too expensive, leading to fewer visits to pharmacies, less treatment, and more frequent health scares. ·      The cost of contraceptives, and medications for those who are diabetic, is one of the largest barriers to access. ·      We're making sure Canadians get the medication that they need, when they need it. Source: https://rb.gy/q9hdml 2. Improving Coverage and Access to Innovative Medicines for Canadians: Standing Committee of Health study of Bill C-64 On May 22, Innovative Medicines Canada - Médicaments novateurs Canada issued a position statement including context, four recommendations and proposed next steps for a collaborative approach. Extracts: Reco #1: The Government of Canada should build on Canada’s extensive existing coverage rather than replacing it with limited public formularies. The limited available funding should be used to address the unique gaps or limitations in coverage in consultation with each jurisdiction. Reco #2: The Government of Canada should leverage existing efforts to reduce costs currently being undertaken by the pan-Canadian Pharmaceutical Alliance (pCPA) through joint pricing negotiations. Standalone federal initiatives would have limited additional benefit. Source: https://rb.gy/ihldbw 3. Addressing the impact of Bill-64: Healthcare experts weigh in on the pros and cons of the new legislation This week, the National Pharmaceutical Congress Institute issued a white paper including survey results and opinions from industry experts. Extracts: ·      “With the advent of AI and technology, we are living in dynamic times when it comes to healthcare...We have to be supportive of any initiative that wants our best interests, even if it’s not perfect and we struggle to please everybody. There’s no perfect system for everyone. The goal is to aim for the best and try to improve”. ·      The majority (over 50%) of surveyed participants also believed the greatest challenge in implementing Bill C-64 could be the lack of provincial cooperation. Source: https://lnkd.in/gVdiyGUS I look forward to participating in the event and hearing from the panel as we continue to see the shaping of Canadian healthcare changes. My name is Arnaud Lavenue and I'm a senior partner at Toc Toc Communications. I'm passionate about bringing pharmaceutical brands to life to their full potential so that they can help the patients who need them most. Thank you for liking, commenting, or following.

62

4 Comments

FibroGen, Inc.'s new CMO, Deyaa Adib, MD isn't fazed by the competition in prostate cancer. Their FG-3246 boasts an impressive 8.7 months PFS in Phase 1, and they're calling out others to show their data! Here's the challenge: PSA isn't the only measure that matters, PFS is key. They believe FG-3246 stacks up well against competitors, even Novartis' Pluvicto. Intrigued? Different companies report data differently, making comparisons tricky. Stay tuned as more info emerges, but FibroGen seems confident they're in the fight! #ProstateCancer #ClinicalTrials #ADC #FibroGen FibroGen throws down the prostate cancer gauntlet | ApexOnco - Clinical Trials news and analysis (oncologypipeline.com)

23

💥 Role of the MSL in Launch Preparedness 💥 Check out this weeks MSL Talk podcast with Matthew Goodwin, Vice President Medical Affairs at scPharmaceuticals who discusses the role of the MSL in preparation and strategy for launch preparedness of new products/indications Learn more about…. 👉 The importance of preparation and timeline for launch 👉 Training and resources for launch mode 👉 The role of field medical leadership 👉 Milestones and success factors to consider 👉 The stressors to be aware of and anticipate during a launch The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

21

2 Comments

👑Royalty Pharma's expanding portfolio...buys in, to the tune of $525M, to the biotech ImmuNext for a cut of Sanofi's acquired MS Drug, frexalimab. 💰 This will yield the right to earn royalties and milestone payments from the autoimmune disease drug, on global sales up to $2B, on a 'tiered royalty structure' Frexalimab’s Potential and Sanofi’s #Strategy 📒 Mid-stage P3 results on this were published in NEJM "Sanofi plans to seek approval for the medicine in 2027, anticipating annual sales of over 5 billion euros (approximately $5.4 billion) and royalties through 2041" 📈 This investment highlights the potential benefits of frexalimab in the treatment of multiple sclerosis (MS) and Royalty Pharma's strategic approach to portfolio diversification. #RMS #MultipleSclerosis #Biotech #Innovation #Sanofi #RoyaltyPharma #Pharma #Healthcare

9

“This is how it has always been done” or “This is how everyone does it” are no longer sufficient. We have to be creative and take risks to disrupt the status quo and forge new paths. #healthcare #clinicaltrials #raredisease

13

2 Comments

I sat down with Fierce Pharma to share insights into the recent flurry of #biopharma acquisitions and the strategic considerations behind them. While large-scale deals dominate headlines there are many advantages for smaller, targeted acquisitions for long-term shareholder returns. These strategic moves provide an opportunity to mitigate risks and foster innovation, particularly in cutting-edge areas like #cellandgenetherapy. Smaller acquisitions may have potential to drive innovation that can help expand your market reach into new modalities and put you on the leading edge of science in front of your competition. By prioritizing talent retention and leveraging clinical data, companies can position themselves for sustained growth and leadership in the competitive #biotech sector. 

69

2 Comments

Another sizable licensing deal East-West. Interestingly, the licensor is not a big pharma. Showing that significant value creation could be captured by small/mid-size Western players. But also how crowded the space could become. #biotech #innovation

9

The countdown is on. Next week, I'm heading to Chicago for the American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24). It's one of the most significant events in the oncology world, bringing together a global community of researchers, clinicians, advocates, and patients in the fight against cancer. For me, #ASCO24 is more than just a conference; it's a chance to: - Dive into the Latest Research: Thousands of abstracts will be presented, showcasing cutting-edge advancements across all aspects of cancer care. I'm eager to learn about new therapies, diagnostic approaches, and breakthroughs that can transform patients' lives. Discussing the evolving landscape of cancer treatment is crucial for staying updated on the latest developments and best practices in patient care. - Connect with Experts: Meeting and exchanging ideas with leading oncologists, scientists, and industry innovators is an invaluable experience. It fosters collaboration and fuels inspiration for advancing cancer care. - Share Our Recent Developments: Zephyr AI team will present a poster and share our findings on the "Evaluation of a Novel Machine Learning Method for PARP Inhibitor Sensitivity Prediction Using Real-World Data." Abstract # 5583 / Poster Bd # 454, presented by Emily Vucic et al., June 3rd, 9 am—12 pm: https://lnkd.in/g8wKqB8v In the meantime, what are you most interested in learning about from #ASCO24? Share your thoughts and questions. See you in Chicago!

27

1 Comment

An often quoted obstacle to the adoption of eConsent is the view of sites, the challenges around training site users, and how to place a new technology within existing site processes. The case study detailed here shows how the Medable team partnered closely with US Renal Care on a challenging consent requirement, providing our standard training modules and delivering a live solution within a matter of 2 weeks, that was expanded to include US Spanish within just another 2 weeks. If you're interested in understanding more about this, and how we can support adoption within your trials then please reach out. #medable #econsent #digitaltrials #remoteconsent

17

"IQVIA estimates that the dearth of a Humira (adalimumab) biosimilars last year cost patients and employers cumulatively $6 billion." #Biosimilars #Adalimumab like #Hulio from #BioconBiologics can provide #affordable #access to #patients and save billions for the Government. #Biosimilars are the way forward for affordable biologics therapy. Read the article: US Specific "The biosimilar Hulio was offered last year at a WAC of $498 for a month's supply, versus $3,461 for Humira, according to a Samsung Bioepis biosimilar report. Still, the vast majority of prescriptions filled in 2023 were for the Humira originator product, prompting market research group IQVIA to conclude that “maintaining patients on Humira comes at a cost of up to about $6 billion per year for patients and employers, compared to a full transition to adalimumab biosimilars.” Biocon Biologics Matt Erick Joshua Salsi https://lnkd.in/gN74FShF

33

🔥 Coming out of one of the Fireside Chat sessions at the 2024 ASGCT Annual Meeting is more on the need for guidelines, a framework of 'global regulatory convergence' in Cell and Gene Therapy, particularly in the development, manufacturing, and access. Leading the discussion is US #FDA's Marks, CBER Director. 🌎 Marks explained to the audience that varied countries' criteria for CGTs, from preclinical testing to manufacturing, make it difficult for patients in certain parts of the world to obtain treatments, particularly those in the rare disease space. Forward-looking: "Five to 10 years from now, Marks’ vision is that there will be enough global regulatory convergence “such that we can get to where we are currently with vaccines” internationally. “It would reduce regulatory burden.”" #ASGCT #CellAndGeneTherapy #CellTherapy #GeneTherapy #RegulatoryAffairs #Oversight #Innovation #Biotech #Healthcare

3

AbbVie today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate to severe ulcerative colitis and moderate to severe Crohn's disease. SKYRIZI is now approved for four indications across immune-mediated inflammatory diseases. "When treating patients with ulcerative colitis, it's important to prioritize both early and sustained clinical remission as well as endoscopic improvement," said Edward Loftus, Jr., M.D., Maxine and Jack Zarrow Family Professor of Gastroenterology in the division of gastroenterology and hepatology at Mayo Clinic in Rochester, Minnesota. "This approval for SKYRIZI is an important step toward addressing these treatment goals." With over 1 million people living with ulcerative colitis, the United States has one of the largest populations affected by this disease and the numbers are continuing to rise. Ulcerative colitis is a form of inflammatory bowel disease (IBD) that causes inflammation in the digestive tract and can result in damage to the colon lining. Patients often experience a range of unpredictable symptoms that impact their daily lives, such as abdominal pain, bloody stool and urgency to use the bathroom. The disease course of ulcerative colitis varies between patients, and in some cases can lead to surgery or complications, including cancer or death. "Today's approval of SKYRIZI for ulcerative colitis expands our IBD portfolio and demonstrates our commitment to helping address ongoing needs of patients," said Roopal Thakkar, M.D., senior vice president, chief medical officer, global therapeutics, AbbVie. "We will continue to invest in transforming the treatment landscape and the lives of people suffering from lBD." Dosing of SKYRIZI for this indication includes a 12-week induction period with three 1200 mg doses delivered every four weeks, followed by maintenance therapy of either 180 mg or 360 mg delivered every eight weeks. Following the induction period, SKYRIZI treatment can be maintained at home using an on-body injector (OBI). The OBI is a hands-free device designed with patients in mind that adheres to the body and takes about five minutes to deliver the medication following preparation steps. #gastroenterology #immunology #ulcerativecolitis #CrohnsDisease  #IBD #SKYRIZI #AbbVie

227

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL   Learn more about….   👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others   The MSL Talk Podcast will be available Tuesday May 14th, 2024 on all podcast platforms and the MSL Talk YouTube Channel.     MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions.   #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers  

15

💥 The Value of In-House Medical Affairs to the MSL 💥 Check out this weeks MSL Talk Podcast with Erlene Seymour, MD, Medical Director, US Medical Affairs Hematology at BeiGene who discusses the value of In House or HQ Medical Affairs to the MSL Learn more about…. 👉 Why is it important for MSLs to know about their inhouse counterparts and what comes from their support 👉 What makes in house medical affairs so valuable to MSLs and to the organization 👉 Advice for MSLs in how they should view and interact with their inhouse counterparts 👉 Advice for MSLs that may want to pursue a role in house or HQ medical affairs position 👉 What is it that helps MSLs stand out and separate themselves from the others The MSL Talk Podcast is available on all podcast platforms and the MSL Talk YouTube Channel. MSL Talk is a podcast that features helpful information for current Medical Science Liaisons, Medical Affairs leaders, job seekers looking to break into the pharmaceutical industry in their first MSL role as well as anyone interested in hearing good industry conversations and medical affairs discussions. #msl #medicalaffairs #medicalscienceliaison #MSLTalk #careers

15

2 Comments